Assessing cost-effectiveness of drug interventions for schizophrenia
- 1 January 2005
- journal article
- research article
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 39 (1-2) , 44-54
Abstract
Objective: To assess from a health sector perspective the incremental cost-effectiveness of eight drug treatment scenarios for established schizophrenia.Keywords
This publication has 38 references indexed in Scilit:
- Summary Australian and New Zealand Clinical Practice Guideline for the Treatment of Schizophrenia 2003Australasian Psychiatry, 2003
- A Comparison of Risperidone and Haloperidol for the Prevention of Relapse in Patients with SchizophreniaNew England Journal of Medicine, 2002
- Patients?? Subjective Experiences of AntipsychoticsCNS Drugs, 2002
- Risperidone in the Treatment of First-Episode Psychotic Patients: A Double-Blind Multicenter StudySchizophrenia Bulletin, 1999
- A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory SchizophreniaNew England Journal of Medicine, 1997
- Towards the improvement of complianceInternational Clinical Psychopharmacology, 1997
- Olanzapine versus Placebo and HaloperidolNeuropsychopharmacology, 1996
- Quetelet's Index and Risk of Colon Cancer in College AlumniJNCI: Journal of the National Cancer Institute, 1992
- Three Lectures on SchizophreniaThe British Journal of Psychiatry, 1980
- Longitudinal Studies of Schizophrenic PatientsSchizophrenia Bulletin, 1980